'In­fe­ri­or ef­fi­ca­cy' leads to pre­ma­ture end of PhI­II for Bay­er's next-gen blood thin­ner asun­dex­i­an

Bay­er is bring­ing a Phase III tri­al for its blood thin­ner asun­dex­i­an to an ear­ly end af­ter the drug showed “in­fe­ri­or ef­fi­ca­cy” against the con­trol arm, the com­pa­ny an­nounced Sun­day.

OCEAN­IC-AF is the first of three large Phase III stud­ies Bay­er has planned for asun­dex­i­an, a top late-stage can­di­date that ex­ec­u­tives said they “con­tin­ue to feel very strong about” as re­cent­ly as the third-quar­ter earn­ings call. It was de­signed to com­pare asun­dex­i­an with Eliquis, or apix­a­ban, a long­stand­ing an­ti­co­ag­u­lant, in 18,000 pa­tients with atri­al fib­ril­la­tion (AF) at risk for stroke. It was orig­i­nal­ly set to con­clude in the sum­mer of 2025, per a clin­i­cal­tri­als.gov list­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER